Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:AIM
DateTimeSourceHeadlineSymbolCompany
05/20/20249:15AMGlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesAMEX:AIMAIM ImmunoTech Inc
05/16/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
05/15/20244:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AIMAIM ImmunoTech Inc
05/09/20248:50AMGlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
05/07/20248:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/07/20248:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/06/20248:30AMGlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
04/29/20248:55AMGlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
04/25/20248:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/18/20248:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/15/20248:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
04/11/202411:00AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/10/20248:21AMGlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
04/02/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
03/28/20248:05AMGlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
03/26/20249:05AMGlobeNewswire Inc.AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
03/25/20249:05AMGlobeNewswire Inc.AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAMEX:AIMAIM ImmunoTech Inc
03/22/20248:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
03/20/20249:25AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
03/15/20248:45AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityAMEX:AIMAIM ImmunoTech Inc
03/07/20248:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Launch of CEO Corner PlatformAMEX:AIMAIM ImmunoTech Inc
02/29/20248:45AMGlobeNewswire Inc.AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateAMEX:AIMAIM ImmunoTech Inc
02/21/202410:37AMEdgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
02/20/20244:34PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:AIMAIM ImmunoTech Inc
02/20/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
02/14/20248:55AMGlobeNewswire Inc.AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
02/09/20243:47PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
02/08/20248:50AMGlobeNewswire Inc.AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAMEX:AIMAIM ImmunoTech Inc
01/25/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
01/24/20249:10AMGlobeNewswire Inc.AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM